Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation?
CONCLUSION: More potent antithrombotic regimens increase bleeding and should only be considered on an individual basis, after careful risk stratification. Accurate risk stratification of ACS patients, for both ischaemic and bleeding risk, is essential to allow individualised treatment.
PMID: 29345587 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Spinthakis N, Farag M, Akhtar Z, Gorog DA Tags: Curr Vasc Pharmacol Source Type: research
More News: Aspirin | Atrial Fibrillation | Bleeding | Cilostazol | Clopidogrel | Drugs & Pharmacology | Hemorrhagic Stroke | Ischemic Stroke | Plavix | Stroke | Study | Vitamin K | Vitamins